591.5000 -0.15 (-0.03%)
NSE Nov 16, 2026 15:31 PM
Volume: 184.1K
 

591.50
-0.03%
Anand Rathi
Jubilant Ingrevia (JUBLINGR) reported ~Rs2bn EBITDA (up 40% y/y and 22% q/q) in Q1FY27, ahead of estimates, driven by strong pricing growth across Nutrition and Health Solutions (NHS) and Chemical Intermediates (CI).
Anand Rathi decreased Buy price target of Jubilant Ingrevia Ltd. to 900.0 on 28 Oct, 2026.
More from Jubilant Ingrevia Ltd.
Recommended